{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:43:29Z","timestamp":1787503409288,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"ANRF-SERB Govt of India","award":["SERB\/CRG-2023\/008460"],"award-info":[{"award-number":["SERB\/CRG-2023\/008460"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12050-z","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:52:08Z","timestamp":1783072328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adapalene inhibits the activity of CD44, a cancer stem cell biomarker in Triple negative breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Shazia","family":"Sofi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowhar","family":"Masoodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shariqa","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Nisar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Mehraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3297-1402","authenticated-orcid":false,"given":"Manzoor Ahmad","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"2","key":"12050_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-020-04222-w","volume":"87","author":"U Mehraj","year":"2021","unstructured":"Mehraj U et al (2021) Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemother Pharmacol 87(2):147\u2013158","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"12050_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209\u2013249","journal-title":"Cancer J Clin"},{"issue":"1130","key":"12050_CR3","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","volume":"95","author":"L Wilkinson","year":"2022","unstructured":"Wilkinson L, Gathani T (2022) Understanding breast cancer as a global health concern. Br J Radiol 95(1130):20211033","journal-title":"Br J Radiol"},{"key":"12050_CR4","doi-asserted-by":"crossref","unstructured":"Ingthorsson S, Traustadottir GA, Gudjonsson T (2025) Breast morphogenesis: From normal development to cancer. A guide to breast cancer research: From cellular heterogeneity and molecular mechanisms to therapy. pp. 29\u201344","DOI":"10.1007\/978-3-031-70875-6_3"},{"key":"12050_CR5","doi-asserted-by":"publisher","first-page":"958443","DOI":"10.3389\/fphar.2022.958443","volume":"13","author":"U Mehraj","year":"2022","unstructured":"Mehraj U et al (2022) Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941. Front Pharmacol 13:958443","journal-title":"Front Pharmacol"},{"issue":"7","key":"12050_CR6","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO (2023) Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics 15(7):1796","journal-title":"Pharmaceutics"},{"key":"12050_CR7","doi-asserted-by":"publisher","first-page":"658552","DOI":"10.3389\/fonc.2021.658552","volume":"11","author":"J Cao","year":"2021","unstructured":"Cao J et al (2021) Chemoresistance and metastasis in breast cancer molecular mechanisms and novel clinical strategies. Front Oncol 11:658552","journal-title":"Front Oncol"},{"issue":"1","key":"12050_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU et al (2024) Unveiling the mechanisms and challenges of cancer drug resistance. Cell Communication Signal 22(1):109","journal-title":"Cell Communication Signal"},{"key":"12050_CR9","doi-asserted-by":"crossref","unstructured":"Maqbool M, Bekele F, Fekadu G (2023) Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets Therapy. p. 15\u201324","DOI":"10.2147\/BCTT.S348060"},{"key":"12050_CR10","doi-asserted-by":"publisher","first-page":"641498","DOI":"10.3389\/fcell.2021.641498","volume":"9","author":"N Jing","year":"2021","unstructured":"Jing N, Gao W-Q, Fang Y-X (2021) Regulation of formation, stemness and therapeutic resistance of cancer stem cells. Front Cell Dev Biology 9:641498","journal-title":"Front Cell Dev Biology"},{"issue":"1","key":"12050_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40169-018-0205-6","volume":"7","author":"W Chen","year":"2018","unstructured":"Chen W, Qin Y, Liu S (2018) Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Clin Translational Med 7(1):27","journal-title":"Clin Translational Med"},{"key":"12050_CR12","unstructured":"Byus G (2023) Breast cancer stem cells & cancer stem cells and their treatments. Microreviews Cell Mol Biology 4"},{"issue":"2","key":"12050_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.7150\/ijbs.76187","volume":"19","author":"L Zhang","year":"2023","unstructured":"Zhang L et al (2023) Targeting breast cancer stem cells. Int J Biol Sci 19(2):552","journal-title":"Int J Biol Sci"},{"key":"12050_CR14","doi-asserted-by":"crossref","unstructured":"Mehraj U et al (2021) The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities. Cell Oncol p. 1\u201321","DOI":"10.1007\/s13402-021-00634-9"},{"issue":"12","key":"12050_CR15","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/biom11121850","volume":"11","author":"M Hassn Mesrati","year":"2021","unstructured":"Hassn Mesrati M et al (2021) CD44: a multifunctional mediator of cancer progression. Biomolecules 11(12):1850","journal-title":"Biomolecules"},{"issue":"1","key":"12050_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40164-020-00192-0","volume":"9","author":"H Xu","year":"2020","unstructured":"Xu H et al (2020) CD44 as a tumor biomarker and therapeutic target. Experimental Hematol Oncol 9(1):36","journal-title":"Experimental Hematol Oncol"},{"key":"12050_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-020-00192-0","volume":"9","author":"H Xu","year":"2020","unstructured":"Xu H et al (2020) CD44 as a tumor biomarker and therapeutic target. Experimental Hematol Oncol 9:1\u201314","journal-title":"Experimental Hematol Oncol"},{"issue":"5","key":"12050_CR18","first-page":"1008","volume":"13","author":"W Zou","year":"2020","unstructured":"Zou W et al (2020) Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer. Int J Clin Exp Pathol 13(5):1008","journal-title":"Int J Clin Exp Pathol"},{"issue":"10","key":"12050_CR19","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.3390\/biomedicines10102488","volume":"10","author":"A Vadhan","year":"2022","unstructured":"Vadhan A et al (2022) CD44 promotes breast cancer metastasis through AKT-mediated downregulation of nuclear FOXA2. Biomedicines 10(10):2488","journal-title":"Biomedicines"},{"issue":"6","key":"12050_CR20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/1568009617666171024165657","volume":"18","author":"X Xie","year":"2018","unstructured":"Xie X et al (2018) Diallyl disulfide inhibits breast cancer stem cell progression and glucose metabolism by targeting CD44\/PKM2\/AMPK signaling. Curr Cancer Drug Targets 18(6):592\u2013599","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"12050_CR21","first-page":"2","volume":"1","author":"A Bojazyah","year":"2021","unstructured":"Bojazyah A, .S.S (2021) Comparative proteomic analysis of differentially expressed proteins in metastatic breast cancer cell lines. response oral hypoglycemic Treat 1(1):2\u20139","journal-title":"response oral hypoglycemic Treat"},{"issue":"3","key":"12050_CR22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.34172\/apb.2021.050","volume":"11","author":"GE Chaudhry","year":"2021","unstructured":"Chaudhry GE et al (2021) Understanding Hyaluronan Receptor (CD44) Interaction, HA-CD44 Activated Potential Targets in Cancer Therapeutics. Adv Pharm Bull 11(3):426\u2013438","journal-title":"Adv Pharm Bull"},{"key":"12050_CR23","doi-asserted-by":"crossref","unstructured":"Cirillo N (2023) The hyaluronan\/CD44 axis: A double-edged sword in cancer. Int J Mol Sci 24(21)","DOI":"10.3390\/ijms242115812"},{"issue":"12","key":"12050_CR24","first-page":"e1291","volume":"5","author":"FU Vaidya","year":"2022","unstructured":"Vaidya FU et al (2022) Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep (Hoboken) 5(12):e1291","journal-title":"Cancer Rep (Hoboken)"},{"issue":"9","key":"12050_CR25","first-page":"2087","volume":"18","author":"Z Liu","year":"2024","unstructured":"Liu Z et al (2024) Hyaluronic acid metabolism and chemotherapy resistance: recent advances and therapeutic potential. Mol Oncol 18(9):2087\u20132106","journal-title":"Mol Oncol"},{"issue":"8","key":"12050_CR26","first-page":"1967","volume":"46","author":"MH Safdar","year":"2018","unstructured":"Safdar MH et al (2018) New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy. Artif Cells Nanomed Biotechnol 46(8):1967\u20131980","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"3","key":"12050_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/1061186X.2025.2550589","volume":"34","author":"S Sofi","year":"2026","unstructured":"Sofi S et al (2026) Combating chemoresistance in breast cancer: exploring tumour microenvironment, combination therapies and drug repurposing strategies. J Drug Target 34(3):336\u2013357","journal-title":"J Drug Target"},{"issue":"15","key":"12050_CR28","doi-asserted-by":"publisher","first-page":"8616","DOI":"10.3390\/ijms23158616","volume":"23","author":"FL Gerardo-Ram\u00edrezM, Keggenhoff","year":"2022","unstructured":"Gerardo-Ram\u00edrezM,Keggenhoff FL, Giam V, Becker D, Groth M, Hartmann N, Straub BK, Morrison H, Galle PR, Marquardt JU, Herrlich P (2022) CD44 contributes to the regulation of MDR1 protein and doxorubicin chemoresistance in osteosarcoma. Int J Mol Sci 23(15):8616. https:\/\/doi.org\/10.3390\/ijms23158616","journal-title":"Int J Mol Sci"},{"key":"12050_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar DS et al (2022) UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 25:18\u201327","journal-title":"Neoplasia"},{"issue":"1","key":"12050_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/pro.3987","volume":"30","author":"A Digre","year":"2021","unstructured":"Digre A, Lindskog C (2021) The human protein atlas\u2014Spatial localization of the human proteome in health and disease. Protein Sci 30(1):218\u2013233","journal-title":"Protein Sci"},{"issue":"W1","key":"12050_CR31","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T et al (2020) TIMER2. 0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 48(W1):W509\u2013W514","journal-title":"Nucleic Acids Res"},{"key":"12050_CR32","doi-asserted-by":"publisher","first-page":"pbaab007","DOI":"10.1093\/database\/baab007","volume":"2021","author":"P J\u00e9z\u00e9quel","year":"2021","unstructured":"J\u00e9z\u00e9quel P et al (2021) bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database 2021:pbaab007","journal-title":"Database"},{"issue":"5","key":"12050_CR33","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/ijms22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B (2021) TNMplot. com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci 22(5):2622","journal-title":"Int J Mol Sci"},{"issue":"2","key":"12050_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ijc.33283","volume":"148","author":"\u00c1 Nagy","year":"2021","unstructured":"Nagy \u00c1, Gy\u0151rffy B (2021) muTarget: a platform linking gene expression changes and mutation status in solid tumors. Int J Cancer 148(2):502\u2013511","journal-title":"Int J Cancer"},{"key":"12050_CR35","doi-asserted-by":"crossref","unstructured":"Mehraj U et al (2022) Adapalene and doxorubicin synergistically promote apoptosis of TNBC Cells by hyperactivation of the ERK1\/2 pathway through ROS induction. Front Oncol 12","DOI":"10.3389\/fonc.2022.938052"},{"issue":"5","key":"12050_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10616-023-00584-0","volume":"75","author":"M Yao","year":"2023","unstructured":"Yao M, Walker G, Gamcsik MP (2023) Assessing MTT and sulforhodamine B cell proliferation assays under multiple oxygen environments. Cytotechnology 75(5):381\u2013390","journal-title":"Cytotechnology"},{"key":"12050_CR37","doi-asserted-by":"crossref","unstructured":"Kadomoto S et al (2025) Development of drug-resistant cell lines for experimental procedures. J Vis Exp 222","DOI":"10.3791\/68957"},{"key":"12050_CR38","doi-asserted-by":"crossref","unstructured":"Qayoom H, Mir MA (2024) Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancer, vol 179. Biomedicine & Pharmacotherapy p 117351","DOI":"10.1016\/j.biopha.2024.117351"},{"issue":"8","key":"12050_CR39","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3390\/cancers12082238","volume":"12","author":"AA Hassan","year":"2020","unstructured":"Hassan AA et al (2020) Selectins: an important family of glycan-binding cell adhesion molecules in ovarian cancer. Cancers 12(8):2238","journal-title":"Cancers"},{"issue":"1","key":"12050_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12935-024-03519-7","volume":"24","author":"Y Ning","year":"2024","unstructured":"Ning Y et al (2024) RhoA-ROCK2 signaling possesses complex pathophysiological functions in cancer progression and shows promising therapeutic potential. Cancer Cell Int 24(1):339","journal-title":"Cancer Cell Int"},{"key":"12050_CR41","doi-asserted-by":"publisher","first-page":"e68447","DOI":"10.7554\/eLife.68447","volume":"10","author":"NJ Toft","year":"2021","unstructured":"Toft NJ et al (2021) Acid-base transporters and pH dynamics in human breast carcinomas predict proliferative activity, metastasis, and survival. Elife 10:e68447","journal-title":"Elife"},{"issue":"1","key":"12050_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/ijms24010103","volume":"24","author":"M Michalczyk","year":"2022","unstructured":"Michalczyk M et al (2022) Hyaluronic acid as a modern approach in anticancer therapy-review. Int J Mol Sci 24(1):103","journal-title":"Int J Mol Sci"},{"issue":"5","key":"12050_CR43","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.18632\/oncotarget.13475","volume":"8","author":"K Hientz","year":"2016","unstructured":"Hientz K et al (2016) The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget 8(5):8921","journal-title":"Oncotarget"},{"issue":"5","key":"12050_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/omi.2021.0025","volume":"25","author":"K Dzobo","year":"2021","unstructured":"Dzobo K, Sinkala M (2021) Cancer stem cell marker CD44 plays multiple key roles in human cancers: Immune suppression\/evasion, drug resistance, epithelial\u2013mesenchymal transition, and metastasis. OMICS 25(5):313\u2013332","journal-title":"OMICS"},{"issue":"1","key":"12050_CR45","doi-asserted-by":"publisher","first-page":"2087204","DOI":"10.1155\/2016\/2087204","volume":"2016","author":"R Thapa","year":"2016","unstructured":"Thapa R, Wilson GD (2016) The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem cells Int 2016(1):2087204","journal-title":"Stem cells Int"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12050-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12050-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12050-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:52:27Z","timestamp":1783072347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12050-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12050"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12050-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflict(s) of interest in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. This study is based entirely on publicly available data, identified datasets obtained from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database. As no human participants or identifiable personal data were directly involved, ethical approval was not required for this study in accordance with institutional and international guidelines for secondary analysis of public data. No human participants or animals were directly involved in this part of the study, and no identifiable patient information was used. For the experimental component of the study involving established cell lines, no ethical approval was required as per institutional and international guidelines, since commercially available and previously established cell lines do not constitute human subject research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"1089"}}